Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 13/20 | 0.77 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.77 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.77 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.58 |
| ▸ | MELK | Q14680 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22932325 | 0.91 | BCL6 (0.86) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL20284171 | 0.90 | BCL6 (0.83) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL25228543 | 0.89 | BCL6 (0.82) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL30486070 | 0.89 | BCL6 (0.82) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL20284173 | 0.89 | BCL6 (0.75) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL30713709 | 0.89 | BCL6 (0.85) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL20284550 | 0.89 | BCL6 (0.85) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL25223209 | 0.88 | BCL6 (0.79) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL20284174 | 0.87 | BCL6 (1.00) | BCL6CHRM4BCL6BNCOR2MELK | |
| SCHEMBL22932326 | 0.87 | BCL6 (1.00) | BCL6CHRM4BCL6BNCOR2MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127909-A1 | Compositions, Systems, and Methods for Modulating a Target Gene | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | disclosed |
| EP-4518903-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR MODULATING A TARGET GENE | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119486762-A | Compositions, systems, and methods for modulating a target gene | 小利兰·斯坦福大学托管委员会 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023215311-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR MODULATING A TARGET GENE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127909-A1 | Compositions, Systems, and Methods for Modulating a Target Gene | MYCBP, SNRPE, RPRD2 | BCL6 591/4885CHRM4 4126/4885BCL6B 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.